Physician profile
Alexis W Perlmutter
NPI 1548490865
$4,225.27
in general payments reported to CMS, 2019-2025
25 companies · $1,523 in 2025
The $1,523 reported for 2025 was more than what a typical Pediatric Dermatology provider received nationally (typical 2025 total: $302).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22.99 · 2021: $224 · 2022: $554 · 2023: $694 · 2024: $1,206 · 2025: $1,523.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,220 · Education: $204.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,219.96 |
| Education | $203.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,190.28 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $316.74 | 2021-2025 | Ilumya, Winlevi, Absorica Ld |
| Janssen Biotech, INC. | $312.45 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Regeneron Healthcare Solutions, INC. | $311.61 | 2019-2025 | Dupixent, Libtayo |
| Glaukos Corporation | $276.80 | 2024-2025 | Idosetr, Idose |
| Alcon Vision LLC | $269.80 | 2025 | Clareon, Rocklatan |
| Genzyme Corporation | $216.43 | 2021-2025 | |
| Ucb, INC. | $209.64 | 2022-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $184.00 | 2022-2025 | |
| Biotissue Holdings INC. | $130.98 | 2025 | |
| Incyte Corporation | $116.25 | 2022-2024 | Opzelura |
| Lilly USA, LLC | $94.88 | 2021-2025 | Olumiant, Taltz, Ebglyss |
| Sanofi-Aventis U.S. LLC | $79.99 | 2025 | |
| Leo Pharma INC. | $77.68 | 2024-2025 | Adbry |
| Amgen INC. | $72.02 | 2023-2024 | Otezla |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $69.44 | 2024-2025 | |
| Dermavant Sciences, INC. | $58.70 | 2022-2023 | Vtama |
| Arcutis Biotherapeutics, INC. | $52.84 | 2023-2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $49.07 | 2022-2025 | Sotyktu |
| Galderma Laboratories, L.P. | $36.53 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.54 | 2025 | Spevigo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $24.40 | 2025 | Siliq, Jublia, Cabtreo |
| Alexion Pharmaceuticals, INC. | $20.86 | 2025 | Koselugo |
| Helsinn Therapeutics (U.S.), INC. | $15.19 | 2021 | |
| Organon LLC | $13.15 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexis Perlmutter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.